KalVista Pharmaceuticals
Update in progressKALV (NGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
KalVista Pharmaceuticals, Inc. is a biopharmaceutical company that develops oral therapies for rare diseases with unmet medical needs. Its lead candidate, EKTERLY, is a fast-acting, potent plasma kallikrein inhibitor for acute attacks of hereditary angioedema (HAE). The company is also advancing an orally disintegrating tablet program, KONFIDENT-KID for pediatric HAE, and KONFIDENT and KONFIDENT-S for adolescents and adults. HQ: Framingham, Massachusetts.
Company score
- Sentiment
- 0.26
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.34
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.11
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.19
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNGM
- LocationUnited States
- CEOMr. Benjamin L. Palleiko
- Employees275
- Websitewww.kalvista.com
Identifiers
- ISINUS4834971032
- FIGIBBG0026ZG5B0
- LEI529900Q7IDA3WUGRZA51
- CUSIP141384107
- CIK0001348911